Preliminary evidence that the novel host-derived immunostimulant EP67 can act as a mucosal adjuvant

Bala Vamsi K Karuturi, Shailendra B. Tallapaka, Joy A. Phillips, Sam D. Sanderson, Joseph A Vetro

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

EP67 is a complement component 5a (C5a)-derived peptide agonist of the C5a receptor (CD88) that selectively activates DCs over neutrophils. Systemic administration of EP67 covalently attached to peptides, proteins, or attenuated pathogens generates TH1-biased immunogen-specific humoral and cellular immune responses with little inflammation. Furthermore, intranasal administration of EP67 alone increases the proportion of activated APCs in the airways. As such, we hypothesized that EP67 can act as a mucosal adjuvant. Intranasal immunization with an EP67-conjugated CTL peptide vaccine against protective MCMV epitopes M84 and pp89 increased protection of naïve female BALB/c mice against primary respiratory infection with salivary gland-derived MCMV and generated higher proportions of epitope responsive and long-lived memory precursor effector cells (MPEC) in the lungs and spleen compared to an inactive, scrambled EP67-conjugated CTL peptide vaccine and vehicle alone. Thus, EP67 may be an effective adjuvant for mucosal vaccines and warrants further study.

Original languageEnglish (US)
Pages (from-to)251-259
Number of pages9
JournalClinical Immunology
Volume161
Issue number2
DOIs
StatePublished - Dec 1 2015

Fingerprint

Immunologic Adjuvants
Subunit Vaccines
Epitopes
Complement C5a
Intranasal Administration
Peptides
Humoral Immunity
Salivary Glands
Cellular Immunity
Respiratory Tract Infections
Immunization
Neutrophils
Vaccines
Spleen
Inflammation
Lung
Proteins

Keywords

  • Host-derived adjuvant
  • Mucosal adjuvant

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Preliminary evidence that the novel host-derived immunostimulant EP67 can act as a mucosal adjuvant. / Karuturi, Bala Vamsi K; Tallapaka, Shailendra B.; Phillips, Joy A.; Sanderson, Sam D.; Vetro, Joseph A.

In: Clinical Immunology, Vol. 161, No. 2, 01.12.2015, p. 251-259.

Research output: Contribution to journalArticle

Karuturi, Bala Vamsi K ; Tallapaka, Shailendra B. ; Phillips, Joy A. ; Sanderson, Sam D. ; Vetro, Joseph A. / Preliminary evidence that the novel host-derived immunostimulant EP67 can act as a mucosal adjuvant. In: Clinical Immunology. 2015 ; Vol. 161, No. 2. pp. 251-259.
@article{ea2ffe124f114b02abe8ddba015467cd,
title = "Preliminary evidence that the novel host-derived immunostimulant EP67 can act as a mucosal adjuvant",
abstract = "EP67 is a complement component 5a (C5a)-derived peptide agonist of the C5a receptor (CD88) that selectively activates DCs over neutrophils. Systemic administration of EP67 covalently attached to peptides, proteins, or attenuated pathogens generates TH1-biased immunogen-specific humoral and cellular immune responses with little inflammation. Furthermore, intranasal administration of EP67 alone increases the proportion of activated APCs in the airways. As such, we hypothesized that EP67 can act as a mucosal adjuvant. Intranasal immunization with an EP67-conjugated CTL peptide vaccine against protective MCMV epitopes M84 and pp89 increased protection of na{\"i}ve female BALB/c mice against primary respiratory infection with salivary gland-derived MCMV and generated higher proportions of epitope responsive and long-lived memory precursor effector cells (MPEC) in the lungs and spleen compared to an inactive, scrambled EP67-conjugated CTL peptide vaccine and vehicle alone. Thus, EP67 may be an effective adjuvant for mucosal vaccines and warrants further study.",
keywords = "Host-derived adjuvant, Mucosal adjuvant",
author = "Karuturi, {Bala Vamsi K} and Tallapaka, {Shailendra B.} and Phillips, {Joy A.} and Sanderson, {Sam D.} and Vetro, {Joseph A}",
year = "2015",
month = "12",
day = "1",
doi = "10.1016/j.clim.2015.06.006",
language = "English (US)",
volume = "161",
pages = "251--259",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Preliminary evidence that the novel host-derived immunostimulant EP67 can act as a mucosal adjuvant

AU - Karuturi, Bala Vamsi K

AU - Tallapaka, Shailendra B.

AU - Phillips, Joy A.

AU - Sanderson, Sam D.

AU - Vetro, Joseph A

PY - 2015/12/1

Y1 - 2015/12/1

N2 - EP67 is a complement component 5a (C5a)-derived peptide agonist of the C5a receptor (CD88) that selectively activates DCs over neutrophils. Systemic administration of EP67 covalently attached to peptides, proteins, or attenuated pathogens generates TH1-biased immunogen-specific humoral and cellular immune responses with little inflammation. Furthermore, intranasal administration of EP67 alone increases the proportion of activated APCs in the airways. As such, we hypothesized that EP67 can act as a mucosal adjuvant. Intranasal immunization with an EP67-conjugated CTL peptide vaccine against protective MCMV epitopes M84 and pp89 increased protection of naïve female BALB/c mice against primary respiratory infection with salivary gland-derived MCMV and generated higher proportions of epitope responsive and long-lived memory precursor effector cells (MPEC) in the lungs and spleen compared to an inactive, scrambled EP67-conjugated CTL peptide vaccine and vehicle alone. Thus, EP67 may be an effective adjuvant for mucosal vaccines and warrants further study.

AB - EP67 is a complement component 5a (C5a)-derived peptide agonist of the C5a receptor (CD88) that selectively activates DCs over neutrophils. Systemic administration of EP67 covalently attached to peptides, proteins, or attenuated pathogens generates TH1-biased immunogen-specific humoral and cellular immune responses with little inflammation. Furthermore, intranasal administration of EP67 alone increases the proportion of activated APCs in the airways. As such, we hypothesized that EP67 can act as a mucosal adjuvant. Intranasal immunization with an EP67-conjugated CTL peptide vaccine against protective MCMV epitopes M84 and pp89 increased protection of naïve female BALB/c mice against primary respiratory infection with salivary gland-derived MCMV and generated higher proportions of epitope responsive and long-lived memory precursor effector cells (MPEC) in the lungs and spleen compared to an inactive, scrambled EP67-conjugated CTL peptide vaccine and vehicle alone. Thus, EP67 may be an effective adjuvant for mucosal vaccines and warrants further study.

KW - Host-derived adjuvant

KW - Mucosal adjuvant

UR - http://www.scopus.com/inward/record.url?scp=84942596824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942596824&partnerID=8YFLogxK

U2 - 10.1016/j.clim.2015.06.006

DO - 10.1016/j.clim.2015.06.006

M3 - Article

VL - 161

SP - 251

EP - 259

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 2

ER -